US3051621A
(en)
*
|
1959-10-22 |
1962-08-28 |
Grove Lab Inc |
Gel composition, pressurized container with same, and method of preparation
|
US3050443A
(en)
*
|
1960-02-16 |
1962-08-21 |
James F Schuyler |
Headache remedy containing ammonia
|
US3039928A
(en)
*
|
1960-03-17 |
1962-06-19 |
Abbott Lab |
Stable aqueous isoproteronol compositions
|
NL262354A
(en)
*
|
1960-03-17 |
|
|
|
US3088874A
(en)
*
|
1960-05-23 |
1963-05-07 |
Union Carbide Corp |
Powder aerosol
|
US3282781A
(en)
*
|
1960-11-25 |
1966-11-01 |
Merck & Co Inc |
Inhalant compositions
|
BE632504A
(en)
*
|
1962-05-24 |
|
|
|
US3169095A
(en)
*
|
1962-10-30 |
1965-02-09 |
Rexall Drug Chemical |
Self-propelling powder-dispensing compositions
|
NL302251A
(en)
*
|
1963-01-28 |
1965-10-11 |
|
|
US3710782A
(en)
*
|
1969-10-01 |
1973-01-16 |
Hauser Res And Eng Co |
Method of treating human skin with a composition for electromedical applications
|
FI770215A
(en)
*
|
1976-01-30 |
1977-07-31 |
Fisons Ltd |
|
AU522792B2
(en)
*
|
1977-07-19 |
1982-06-24 |
Fisons Plc |
Pressure pack formulation
|
US4352789A
(en)
*
|
1980-03-17 |
1982-10-05 |
Minnesota Mining And Manufacturing Company |
Aerosol compositions containing finely divided solid materials
|
US4655231A
(en)
*
|
1984-01-09 |
1987-04-07 |
Advanced Tobacco Products, Inc. |
Snuff and preparation thereof
|
US4576949A
(en)
*
|
1984-05-07 |
1986-03-18 |
The Upjohn Company |
Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
|
EP0213108A3
(en)
*
|
1985-06-26 |
1987-07-15 |
Kurt Dr. Burghart |
Pharmaceutical preparation containing an antihypotonic as the active agent
|
JPH0645538B2
(en)
*
|
1987-09-30 |
1994-06-15 |
日本化薬株式会社 |
Nitroglycerin spray
|
FR2625677A1
(en)
*
|
1988-01-07 |
1989-07-13 |
Cosnier Alain |
Medicinal composition intended for administration in aerosol form
|
EP0338670B1
(en)
*
|
1988-03-22 |
1994-05-11 |
FISONS plc |
Pharmaceutical Compositions
|
US5776434A
(en)
*
|
1988-12-06 |
1998-07-07 |
Riker Laboratories, Inc. |
Medicinal aerosol formulations
|
US5225183A
(en)
*
|
1988-12-06 |
1993-07-06 |
Riker Laboratories, Inc. |
Medicinal aerosol formulations
|
US5439670A
(en)
*
|
1989-11-28 |
1995-08-08 |
Riker Laboratories, Inc. |
Medicinal aerosol formulations
|
DE4003270A1
(en)
*
|
1990-02-03 |
1991-08-08 |
Boehringer Ingelheim Kg |
NEW SPEED GASES AND THEIR USE IN MEDICINE PREPARATIONS
|
US5118494A
(en)
*
|
1990-03-23 |
1992-06-02 |
Minnesota Mining And Manufacturing Company |
Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
|
US5175152A
(en)
*
|
1990-09-28 |
1992-12-29 |
Singh Nikhilesh N |
Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
|
MX9203481A
(en)
*
|
1990-10-18 |
1992-07-01 |
Minnesota Mining & Mfg |
FORMULATIONS.
|
US5785952A
(en)
*
|
1990-11-09 |
1998-07-28 |
Glaxo Group Limited |
Aerosol medicament formulation having a surface coating of surfactant
|
US5919435A
(en)
|
1990-11-09 |
1999-07-06 |
Glaxo Group Limited |
Aerosol formulation containing a particulate medicament
|
YU59192A
(en)
|
1991-06-10 |
1994-12-28 |
Schering Corporation |
FORMULATION OF AEROSOLS NOT CONTAINING CHLOROFLUORO-CARBON COMPOUNDS
|
US5234933A
(en)
*
|
1991-10-31 |
1993-08-10 |
Board Of Governors Of Wayne State University And Vanderbilt University |
Cyclic hydroxamic acids
|
IL104068A
(en)
*
|
1991-12-12 |
1998-10-30 |
Glaxo Group Ltd |
Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
|
US5658549A
(en)
*
|
1991-12-12 |
1997-08-19 |
Glaxo Group Limited |
Aerosol formulations containing propellant 134a and fluticasone propionate
|
US5736124A
(en)
*
|
1991-12-12 |
1998-04-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicament
|
US5744123A
(en)
*
|
1991-12-12 |
1998-04-28 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
US5683676A
(en)
*
|
1991-12-12 |
1997-11-04 |
Glaxo Group Limited |
Canister containing aerosol formulations containing P134a and particulate medicaments
|
ES2079210T3
(en)
*
|
1991-12-12 |
1996-01-01 |
Glaxo Group Ltd |
PHARMACEUTICAL FORMULATION OF AEROSOL.
|
US5674471A
(en)
*
|
1991-12-12 |
1997-10-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and salbutamol
|
JP3026841B2
(en)
*
|
1991-12-12 |
2000-03-27 |
グラクソ、グループ、リミテッド |
Medicine
|
US5916540A
(en)
*
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
US7105152B1
(en)
|
1991-12-18 |
2006-09-12 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
DK1086688T3
(en)
|
1991-12-18 |
2004-08-16 |
Minnesota Mining & Mfg |
Aerosol formulations for suspensions
|
RU2126248C1
(en)
*
|
1992-12-09 |
1999-02-20 |
Берингер Ингельхейм Фармасьютикалз, Инк. |
Liquid pharmaceutical composition as an aerosol
|
ATE163006T1
(en)
*
|
1993-06-01 |
1998-02-15 |
Ono Pharmaceutical Co |
PENTANIC ACID DERIVATIVES
|
EP0640609A1
(en)
*
|
1993-08-24 |
1995-03-01 |
Ono Pharmaceutical Co., Ltd. |
Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
|
CA2137106C
(en)
*
|
1993-12-03 |
2000-02-08 |
Hisao Nakai |
Amidinophenol derivatives
|
AU680967B2
(en)
*
|
1993-12-20 |
1997-08-14 |
Minnesota Mining And Manufacturing Company |
Flunisolide aerosol formulations
|
DK0703216T3
(en)
|
1994-09-20 |
1999-10-18 |
Ono Pharmaceutical Co |
Amidinophenol derivatives as protease inhibitors
|
US5679287A
(en)
*
|
1995-04-28 |
1997-10-21 |
Great Lakes Chemical Corporation |
Uses of heptafluoropropane
|
US5840213A
(en)
*
|
1995-04-28 |
1998-11-24 |
Great Lakes Chemical Corporation |
Uses of heptafluoropropane
|
KR980009238A
(en)
|
1995-07-28 |
1998-04-30 |
우에노 도시오 |
Sulfonyl amino acid derivative
|
PT757984E
(en)
*
|
1995-08-08 |
2003-02-28 |
Ono Pharmaceutical Co |
UTEIS HYDROXAMIC ACID DERIVATIVES TO INHIBIT GELATINASE
|
AUPN814496A0
(en)
*
|
1996-02-19 |
1996-03-14 |
Monash University |
Dermal penetration enhancer
|
US5861268A
(en)
*
|
1996-05-23 |
1999-01-19 |
Biomide Investment Limited Partnership |
Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
|
US6054488A
(en)
*
|
1996-06-11 |
2000-04-25 |
3M Innovative Properties Company |
Medicinal aerosol formulations of formoterol
|
GB9616237D0
(en)
|
1996-08-01 |
1996-09-11 |
Norton Healthcare Ltd |
Aerosol formulations
|
AU718967B2
(en)
|
1997-02-05 |
2000-05-04 |
Jagotec Ag |
Medical aerosol formulations
|
US6129905A
(en)
*
|
1997-04-21 |
2000-10-10 |
Aeropharm Technology, Inc. |
Aerosol formulations containing a sugar as a dispersant
|
US5891420A
(en)
*
|
1997-04-21 |
1999-04-06 |
Aeropharm Technology Limited |
Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
|
US5891419A
(en)
*
|
1997-04-21 |
1999-04-06 |
Aeropharm Technology Limited |
Environmentally safe flunisolide aerosol formulations for oral inhalation
|
US7153866B1
(en)
*
|
1997-05-27 |
2006-12-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
|
US20010031244A1
(en)
*
|
1997-06-13 |
2001-10-18 |
Chiesi Farmaceutici S.P.A. |
Pharmaceutical aerosol composition
|
JPH11187882A
(en)
|
1997-12-26 |
1999-07-13 |
Ono Pharmaceut Co Ltd |
Novel polypeptide, its production, cdna coding for the same polypeptide, vector comprising the same cdna, host cell transformed by the same vector, antibody of the same polypeptide, and pharmaceutical composition containing the polypeptide of antibody
|
WO2000006121A1
(en)
|
1998-07-24 |
2000-02-10 |
Jago Research Ag |
Medicinal aerosol formulations
|
CN1150890C
(en)
|
1998-08-04 |
2004-05-26 |
杰格研究股份公司 |
Medicinal aerosol formulations
|
US6458338B1
(en)
|
1998-09-22 |
2002-10-01 |
Aeropharm Technology Incorporated |
Amino acid stabilized medicinal aerosol formulations
|
US6136294C1
(en)
*
|
1998-09-22 |
2002-09-24 |
Aeropharm Technology Inc |
Amino acid stabilized medical aerosol formulation
|
DZ2947A1
(en)
*
|
1998-11-25 |
2004-03-15 |
Chiesi Farma Spa |
Pressure metered dose inhaler.
|
US6315985B1
(en)
*
|
1999-06-18 |
2001-11-13 |
3M Innovative Properties Company |
C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
MXPA04000757A
(en)
|
2001-07-23 |
2004-07-08 |
Ono Pharmaceutical Co |
Remedies for diseases with bone mass loss having ep4.
|
NZ534712A
(en)
|
2002-02-19 |
2006-11-30 |
Ono Pharmaceutical Co |
Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
|
US7582284B2
(en)
*
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
US20050186141A1
(en)
*
|
2002-06-25 |
2005-08-25 |
Acrux Dds Pty Ltd. |
Transdermal aerosol compositions
|
EA009024B1
(en)
*
|
2002-06-25 |
2007-10-26 |
АКРУКС ДиДиЭс ПиТиУай ЭлТиДи |
Pharmaceutical composition for transdermal delivery of an active agent (variants)
|
US20050181032A1
(en)
*
|
2002-06-25 |
2005-08-18 |
Acrux Dds Pty Ltd. |
Metastable pharmaceutical compositions
|
JPWO2004002531A1
(en)
|
2002-06-26 |
2005-10-27 |
小野薬品工業株式会社 |
Treatment for diseases caused by contraction or dilation of blood vessels
|
EP3287144A1
(en)
|
2002-07-03 |
2018-02-28 |
ONO Pharmaceutical Co., Ltd. |
Immunopotentiating compositions
|
TW200408393A
(en)
|
2002-10-03 |
2004-06-01 |
Ono Pharmaceutical Co |
Antagonist of lysophosphatidine acid receptor
|
WO2004032965A1
(en)
|
2002-10-10 |
2004-04-22 |
Ono Pharmaceutical Co., Ltd. |
Endogenous repair factor production promoters
|
AU2003272962A1
(en)
*
|
2002-10-10 |
2004-05-04 |
Shuh Narumiya |
Remedies for allergic diseases
|
EP1591527B1
(en)
|
2003-01-23 |
2015-08-26 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human pd-1
|
NZ542304A
(en)
|
2003-03-14 |
2009-07-31 |
Ono Pharmaceutical Co |
Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
|
US7498323B2
(en)
|
2003-04-18 |
2009-03-03 |
Ono Pharmaceuticals Co., Ltd. |
Spiro-piperidine compounds and medicinal use thereof
|
WO2004103364A2
(en)
*
|
2003-05-16 |
2004-12-02 |
Arriva Pharmaceuticals, Inc. |
Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
|
US20050069918A1
(en)
*
|
2003-05-29 |
2005-03-31 |
Francois Claret |
JAB1 as a prognostic marker and a therapeutic target for human cancer
|
JP4666257B2
(en)
|
2003-07-25 |
2011-04-06 |
小野薬品工業株式会社 |
Cartilage-related disease treatment
|
JP4947406B2
(en)
|
2003-08-29 |
2012-06-06 |
小野薬品工業株式会社 |
Compound having S1P receptor binding ability and pharmaceutical use thereof
|
US7763610B2
(en)
|
2003-09-01 |
2010-07-27 |
Ono Pharmaceutical Co., Ltd. |
Carboxylic acid derived benzoxazines as agents for the treatment of respiratory diseases
|
JP2007505136A
(en)
*
|
2003-09-10 |
2007-03-08 |
マツプ・フアーマシユーテイカルズ・インコーポレーテツド |
Aerosol formulation for delivering dihydroergotamine to systemic circulation by pulmonary inhalation
|
KR20060106823A
(en)
*
|
2003-10-20 |
2006-10-12 |
쉐링 코포레이션 |
Pharmaceutical aerosol compositions
|
EP1698375B1
(en)
|
2003-12-25 |
2014-04-02 |
Ono Pharmaceutical Co., Ltd. |
Azetidine ring compounds and drugs comprising the same
|
US20060018840A1
(en)
*
|
2004-06-28 |
2006-01-26 |
Nektar Therapeutics |
Aerosolizable formulation comprising nicotine
|
EP2465538A3
(en)
|
2004-10-21 |
2013-11-20 |
Ono Pharmaceutical Co., Ltd. |
Use of immunesuppressant receptor
|
SI1814538T1
(en)
*
|
2004-11-24 |
2010-01-29 |
Alcon Inc |
Method of delivering nasal spray
|
WO2006084041A2
(en)
|
2005-02-02 |
2006-08-10 |
Mitos Pharmaceuticals, Inc. |
Nitroxides for use in treating or preventing diabetes
|
US8524735B2
(en)
*
|
2005-05-18 |
2013-09-03 |
Mpex Pharmaceuticals, Inc. |
Aerosolized fluoroquinolones and uses thereof
|
CA2608273C
(en)
|
2005-05-18 |
2015-10-20 |
Mpex Pharmaceuticals, Inc. |
Aerosolized fluoroquinolones and uses thereof
|
EP1890732B1
(en)
|
2005-06-17 |
2018-03-28 |
Wisconsin Alumni Research Foundation |
Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
|
DK1942108T3
(en)
|
2005-10-28 |
2013-12-09 |
Ono Pharmaceutical Co |
Compound containing basic group and use thereof
|
EP1961745A1
(en)
|
2005-12-12 |
2008-08-27 |
Ono Pharmaceutical Co., Ltd. |
Bicyclic heterocyclic compound
|
JPWO2007069671A1
(en)
|
2005-12-15 |
2009-05-21 |
小野薬品工業株式会社 |
Bicyclic heterocyclic compounds
|
US20070286814A1
(en)
*
|
2006-06-12 |
2007-12-13 |
Medispray Laboratories Pvt. Ltd. |
Stable aerosol pharmaceutical formulations
|
ES2538082T3
(en)
*
|
2007-02-11 |
2015-06-17 |
Map Pharmaceuticals Inc |
Therapeutic administration method of DHE to allow rapid migraine relief while minimizing the side effects profile
|
TW200902019A
(en)
|
2007-04-26 |
2009-01-16 |
Ono Pharmaceutical Co |
Dicyclic heterocyclic compound
|
DE102008007198A1
(en)
|
2008-02-01 |
2009-08-13 |
Infectopharm Arzneimittel Und Consilium Gmbh |
Oral or nasally administrable formulations containing epinephrine with improved properties
|
EP2346509B1
(en)
*
|
2008-10-07 |
2020-05-13 |
Horizon Orphan LLC |
Inhalation of levofloxacin for reducing lung inflammation
|
DK2344129T3
(en)
|
2008-10-07 |
2018-05-07 |
Horizon Orphan Llc |
AEROSOL FLUOROQUINOLONE FORMULATIONS FOR IMPROVED PHARMACOKINETICS
|
TWI469965B
(en)
|
2008-12-22 |
2015-01-21 |
Ono Pharmaceutical Co |
Ethynylindole compounds
|
JP5621771B2
(en)
|
2009-06-17 |
2014-11-12 |
小野薬品工業株式会社 |
New imidazopyridine compounds
|
WO2010151804A1
(en)
*
|
2009-06-26 |
2010-12-29 |
Map Pharmaceuticals, Inc. |
Administration of dihydroergotamine mesylate particles using a metered dose inhaler
|
EP2473170B1
(en)
|
2009-09-04 |
2019-06-19 |
Horizon Orphan LLC |
Use of aerosolized levofloxacin for treating cystic fibrosis
|
WO2011066537A1
(en)
|
2009-11-30 |
2011-06-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
|
AU2011270297B2
(en)
|
2010-06-21 |
2014-07-03 |
Ono Pharmaceutical Co., Ltd. |
Novel crystalline forms of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy] phenyl}ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid,4,4'- [2-methyl-7-({4-[4-(pentafluorophenyl) butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4'-[4-fluoro-2-methyl-7- ({4-[4-(2,3,4,6-tetrafluorophenyl) butoxy]phenyl}ethynyl)-1h-indole-1,3-diyl]dibutanoic acid
|
PL2647619T3
(en)
|
2010-12-02 |
2015-08-31 |
Ono Pharmaceutical Co |
Novel compound and medical use thereof
|
EP4059499A1
(en)
|
2011-01-31 |
2022-09-21 |
Avalyn Pharma Inc. |
Aerosol pirfenidone and pyridone analog compounds and uses thereof
|
ES2587856T3
(en)
|
2011-03-18 |
2016-10-27 |
Ono Pharmaceutical Co., Ltd. |
Tetrahydrocarboline derivative
|
JP6160613B2
(en)
|
2012-04-26 |
2017-07-12 |
小野薬品工業株式会社 |
Trk inhibitory compound
|
TWI567068B
(en)
|
2013-02-19 |
2017-01-21 |
小野藥品工業股份有限公司 |
Trk inhibitor compound
|
EP3027026A4
(en)
|
2013-07-31 |
2017-05-03 |
Windward Pharma, Inc. |
Aerosol tyrosine kinase inhibitor compounds and uses thereof
|
WO2015106150A1
(en)
|
2014-01-10 |
2015-07-16 |
Genoa Pharmaceuticals Inc. |
Aerosol pirfenidone and pyridone analog compounds and uses thereof
|
JP2017504628A
(en)
|
2014-01-31 |
2017-02-09 |
小野薬品工業株式会社 |
Condensed imidazole compounds
|
WO2018101309A1
(en)
|
2016-11-30 |
2018-06-07 |
大日本住友製薬株式会社 |
Wt1 helper peptide, and combination of said peptide and cancer antigen peptide conjugate
|
US20210100886A1
(en)
|
2017-03-30 |
2021-04-08 |
Sumitomo Dainippon Pharma Co., Ltd. |
Wt1 cancer antigen peptides and peptide conjugates comprising the peptides
|
WO2019049891A1
(en)
|
2017-09-06 |
2019-03-14 |
小野薬品工業株式会社 |
METHOD FOR TREATING CANCER BY COMBINATION OF Trk INHIBITOR AND KINASE INHIBITOR
|
WO2019230919A1
(en)
|
2018-05-31 |
2019-12-05 |
小野薬品工業株式会社 |
Biomarker for judging efficacy of immune checkpoint inhibitor
|
TW202028212A
(en)
|
2018-10-11 |
2020-08-01 |
日商小野藥品工業股份有限公司 |
Sting agonist compound
|
US20220283167A1
(en)
|
2019-08-05 |
2022-09-08 |
Ono Pharmaceutical Co., Ltd. |
Biomarkers for determining the efficacy of immune checkpoint inhibitors
|
JPWO2021107125A1
(en)
|
2019-11-29 |
2021-06-03 |
|
|
EP4134134A4
(en)
|
2020-04-10 |
2023-12-27 |
ONO Pharmaceutical Co., Ltd. |
Sting agonistic compound
|
WO2021230247A1
(en)
|
2020-05-12 |
2021-11-18 |
大日本住友製薬株式会社 |
Pharmaceutical composition for treating cancer
|
WO2022240897A1
(en)
|
2021-05-10 |
2022-11-17 |
Sepelo Therapeutics, Llc |
Pharmaceutical composition comprising delafloxacin for administration into the lung
|
WO2022251679A1
(en)
|
2021-05-27 |
2022-12-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nitroxide radicals for use as antiviral treatment for coronavirus infection
|
WO2023028364A1
(en)
|
2021-08-27 |
2023-03-02 |
Sepelo Therapeutics, Llc |
Targeted compositions and uses therof
|